Early research (Phase 1)Study completedNCT02583594
What this trial is testing
Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
Who this might be right for
Progressive Multiple Sclerosis
Genzyme, a Sanofi Company 24